{
    "2021-06-20": [
        [
            {
                "time": "",
                "original_text": "周彩存教授：埃克替尼成为全球首个获批辅助治疗适应证的第一代EGFR TKI，EVIDENCE提供高级别循证医学证据",
                "features": {
                    "keywords": [
                        "埃克替尼",
                        "全球首个",
                        "辅助治疗",
                        "EGFR TKI",
                        "EVIDENCE",
                        "循证医学证据"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}